Cabazitaxel
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CABAZITAXEL |
|---|---|
| Type | Drug |
| Aliases | Jevtana |
| Status | reviewed 2026-05-07 |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CARD-DE-BONO-2019 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 SRC-TROPIC-DE-BONO-2010 |
Drug Facts
| Class | Taxane antineoplastic agent |
|---|---|
| Mechanism | Semisynthetic taxane that binds tubulin, stabilizes microtubules, and blocks mitotic and interphase cellular functions. Used in prostate cancer after docetaxel exposure, typically with prednisone and G-CSF support. |
| Typical dosing | mCRPC post-docetaxel: 20 mg/m2 IV every 21 days with prednisone; 25 mg/m2 may be used in selected fit patients. Primary G-CSF prophylaxis is used for high-risk patients and is commonly favored with 25 mg/m2 dosing. |
| Ukraine registered | False |
| NSZU reimbursed | False |
Warnings
- Neutropenia
- Severe hypersensitivity
Notes
Thin drug entity added to resolve regimen component references from REG-CABAZITAXEL-MCRPC. Detailed availability and dose-modification metadata should be expanded during prostate V1/V2 curation.
Used By
Regimens
REG-CABAZITAXEL-MCRPC- Cabazitaxel (mCRPC, 2L)